| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037989652 |
| P356 | DOI | 10.1038/311067A0 |
| P698 | PubMed publication ID | 6472464 |
| P50 | author | Robert H. Purcell | Q2157414 |
| Geoffrey Lilley Smith | Q5069186 | ||
| Bernard Moss | Q822617 | ||
| John L. Gerin | Q1700748 | ||
| P2860 | cites work | Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen | Q45794061 |
| Use of and interpretation of results using inocula of hepatitis B virus with known infectivity titers | Q45794085 | ||
| Expression of the hepatitis B virus surface, core and E antigen genes by stable rat and mouse cell lines | Q45799064 | ||
| Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus | Q45804460 | ||
| Hepatitis B Virus Infection in Chimpanzees: Titration of Subtypes | Q45883096 | ||
| Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides | Q59094245 | ||
| Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides | Q59096906 | ||
| Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States | Q72150100 | ||
| Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff | Q72452766 | ||
| Prediction of protein antigenic determinants from amino acid sequences | Q29547548 | ||
| Expression of hepatitis B surface antigen gene in yeast | Q34055398 | ||
| Expression of the hepatitis B virus surface antigen gene in cell culture by using a simian virus 40 vector | Q35355405 | ||
| Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles | Q35373888 | ||
| Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. | Q36245488 | ||
| Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide | Q36278570 | ||
| Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant | Q36304771 | ||
| Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus | Q36307754 | ||
| Vaccinia virus: a selectable eukaryotic cloning and expression vector | Q36324116 | ||
| Specificity of antibodies elicited by a synthetic peptide having a sequence in common with a fragment of a virus protein, the hepatitis B surface antigen | Q36327658 | ||
| Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA. | Q36401094 | ||
| General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. | Q36913229 | ||
| Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin | Q37347836 | ||
| Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters | Q37508631 | ||
| Synthesis of hepatitis B surface antigen in mammalian cells: expression of the entire gene and the coding region | Q40138161 | ||
| Expression of hepatitis B virus surface antigen in yeast | Q40491140 | ||
| Plasmid-Directed Synthesis of Hepatitis B Surface Antigen in Monkey Cells | Q40673584 | ||
| Expression of hepatitis B surface antigen in unselected cell culture transfected with recircularized HBV DNA | Q41315049 | ||
| Synthesis and assembly of hepatitis B virus surface antigen particles in yeast | Q45793098 | ||
| P433 | issue | 5981 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Vaccinia virus | Q1986297 |
| P304 | page(s) | 67-69 | |
| P577 | publication date | 1984-09-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Live recombinant vaccinia virus protects chimpanzees against hepatitis B. | |
| P478 | volume | 311 |
| Q36787928 | A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection |
| Q38353693 | A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus |
| Q44035641 | A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees |
| Q33349721 | A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA) |
| Q36099144 | A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge |
| Q35861566 | A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. |
| Q36896352 | Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity |
| Q35652068 | Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax |
| Q40865882 | Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target |
| Q74539555 | Cancer vaccines |
| Q35948047 | Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model |
| Q44106019 | Chimpanzee adenoviral vectors as vaccines for outbreak pathogens |
| Q34478724 | Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus |
| Q40664205 | Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. |
| Q64114895 | Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes |
| Q93647942 | Controversies in immunization against hepatitis B |
| Q37495259 | DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines |
| Q44567701 | DNA-based immunization against hepatitis B virus |
| Q45827796 | Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype |
| Q37949279 | Development of new cell lines for animal cell biotechnology |
| Q36826782 | Distinctive properties of the hepatitis B virus envelope proteins |
| Q40129489 | Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene |
| Q45763280 | Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants |
| Q37248017 | Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection |
| Q40754536 | Engineered human vaccines |
| Q41677468 | Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite |
| Q28727937 | Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA |
| Q36851214 | Expression of Sindbis virus structural proteins via recombinant vaccinia virus: synthesis, processing, and incorporation into mature Sindbis virions |
| Q34340404 | Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection |
| Q36113480 | Expression of recombinant proteins on the surface of the coagulase-negative bacterium Staphylococcus xylosus |
| Q39500655 | Expression of the HTLV-III envelope gene by a recombinant vaccinia virus |
| Q36875391 | Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant |
| Q36966584 | Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria. |
| Q36905047 | Genetic determinants of resistance to ectromelia (mousepox) virus-induced mortality |
| Q37249251 | Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety |
| Q38705483 | Genomic characterization of a poxvirus isolated from a child |
| Q33926692 | Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus |
| Q41657342 | Highly efficient expression of proteins encoded by recombinant vaccinia virus in lymphocytes |
| Q34162769 | Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. |
| Q26786772 | Immune-mediated Liver Injury in Hepatitis B Virus Infection |
| Q34539879 | Immunization delivered by lentiviral vectors for cancer and infectious diseases |
| Q36866184 | Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection |
| Q34301871 | Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus |
| Q33932227 | In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses |
| Q36798603 | Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses |
| Q38525448 | Induction of CTL responses and identification of a novel epitope of hepatitis B virus surface antigens in C57BL/6 mice immunized with recombinant vaccinia viruses |
| Q36751598 | Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector |
| Q27486585 | Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus |
| Q37705604 | Investigating Viruses during the Transformation of Molecular Biology |
| Q36852967 | Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus |
| Q40596089 | Microneedle-mediated delivery of viral vectored vaccines |
| Q40962256 | Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants |
| Q38300425 | Natural history of chronic hepatitis B virus infection |
| Q34490083 | New hepatitis B vaccines |
| Q38155879 | New technology for prevention and control of infectious bovine respiratory diseases |
| Q35099708 | Next generation: tuberculosis vaccines that elicit protective CD8+ T cells |
| Q40059020 | Novel viral vectors in infectious diseases |
| Q36665647 | Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques |
| Q33925491 | Pathogenesis of hepatitis B virus infection |
| Q44030663 | Prevention of vertical transmission of Neospora caninum in BALB/c mice by recombinant vaccinia virus carrying NcSRS2 gene |
| Q43696302 | Priming effect of recombinant vaccinia virus coding for the middle hepatitis B surface antigen |
| Q33731344 | Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines |
| Q43631632 | Prospects for second and third generation hepatitis B vaccines |
| Q39517633 | Prospects for vaccines against HIV |
| Q35865836 | Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein. |
| Q24606451 | Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene |
| Q36869697 | Protection of chimpanzees from type B hepatitis by immunization with woodchuck hepatitis virus surface antigen |
| Q45837672 | Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine |
| Q37333844 | Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen |
| Q40829474 | Protective efficacy of vaccination by recombinant vaccinia virus against Neospora caninum infection |
| Q84315555 | Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus |
| Q64100856 | Recent advances in the development of gene delivery systems |
| Q51007512 | Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. |
| Q34636530 | Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters |
| Q37123441 | Recombinant lentivector as a genetic immunization vehicle for antitumor immunity |
| Q41430227 | Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. |
| Q45796200 | Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells |
| Q37126266 | Reflections on the early development of poxvirus vectors |
| Q36086213 | Replication-Competent Controlled Herpes Simplex Virus |
| Q35596022 | Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein |
| Q37202173 | Response of dairy calves to vaccinia viruses that express foreign genes |
| Q90607894 | Role of alcohol in pathogenesis of hepatitis B virus infection |
| Q92404259 | SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells |
| Q36886949 | Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes. |
| Q36696504 | Sickness and recovery of dogs challenged with a street rabies virus after vaccination with a vaccinia virus recombinant expressing rabies virus N protein |
| Q42540926 | Synthesis and antiviral evaluation of analogs of adenosine-N1-oxide and 1-(Benzyloxy)adenosine |
| Q36895157 | Synthesis of bovine growth hormone in primates by using a herpesvirus vector |
| Q36827447 | Synthesis, cellular location, and immunogenicity of bovine herpesvirus 1 glycoproteins gI and gIII expressed by recombinant vaccinia virus |
| Q45831257 | Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response |
| Q35664171 | The chimpanzee model for hepatitis B virus infection |
| Q59051957 | The hepatitis B virus |
| Q87098753 | The live vector approach-viruses |
| Q50115667 | Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. |
| Q38775588 | Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine |
| Q38112854 | Utilizing poxviral vectored vaccines for antibody induction-progress and prospects |
| Q36117060 | Vaccinia recombinants as vaccine vectors |
| Q36952733 | Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques |
| Q38776417 | Vaccinia virus expression vectors |
| Q36523222 | Vaccinia virus protein C4 inhibits NF-κB activation and promotes virus virulence. |
| Q40129351 | Vaccinia virus recombinants expressing an 11-kilodalton beta-galactosidase fusion protein incorporate active beta-galactosidase in virus particles. |
| Q34211635 | Vaccinia virus vectors: new strategies for producing recombinant vaccines |
| Q37158473 | Vaccinia virus, a promising new therapeutic agent for pancreatic cancer |
| Q40983004 | Vaccinia virus-induced apoptosis in immature B lymphocytes: role of cellular Bcl-2. |
| Q38677050 | Vaccinia virus: a suitable vehicle for recombinant vaccines? |
| Q37755852 | Vaccinia virus: a tool for research and vaccine development |
| Q39734444 | Vaccinia virus: an expression vector for genes from parasites |
| Q30996881 | Vaxvec: The first web-based recombinant vaccine vector database and its data analysis |
| Q93535905 | Viral hepatitis |
| Q41812230 | Viral vectors for vaccine applications |
| Q37646066 | Viruses as vaccine vectors for infectious diseases and cancer |
| Q34343808 | What next for botulism vaccine development? |
| Q39649765 | What to expect of a good vaccine and how to achieve it. |
Search more.